UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Explore criteria to identify altcoins safe for long-term holding, including fundamentals, liquidity, and community support. Start evaluating with confidence.
27,729 articlesAs UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
A clear, investor-friendly look at Iridex's Q1 2026 performance and what it could mean for the full year. Learn the n...
SCHD has surged in 2026, outpacing the S&P 500 as dividend-growth funds draw cash-flow hungry investors. Three core E...
When Warren Buffett stepped aside, Greg Abel took the wheel at Berkshire Hathaway. This article breaks down his first...
May surprised many investors with broad gains across major asset classes. This guide breaks down who led, why, and pr...
Nvidia sits at the center of a rapid AI infrastructure buildout. Here’s how the stock could move by 2029, based on gr...
Marvell Technology has bold dreams about joining the trillion-dollar club. This article lays out a practical timeline...
As markets push higher, investors wonder if a downturn is inevitable. This guide dives into history, current signals,...
A director’s stock sale can spark worry, but not every insider move is a warning. This guide shows how to assess trad...
Gold ETFs still track spot prices, but GLD's 0.40% expense ratio is quietly eroding long-term gains. Through mid-2026...
Macerich faces a retail landscape that’s evolved in 2025. This deep dive breaks down the factors shaping macerich (ma...
When a prominent fund makes a sizable stake reduction, it often signals more than profit-taking. This article breaks ...